Primagen and University of British Columbia enter into worldwide licensing agreement for mitochondrial DNA toxicity technology

10-Sep-2003
AMSTERDAM. Primagen Holding B.V., a provider of molecular diagnostic tests for infectious diseases, AIDS and cancer, announced today it has entered into an exclusive worldwide licensing agreement to commercialize the mitochondrial DNA detection and toxicity technology developed by the University of British Columbia, Vancouver, Canada. "This license is a further fortification of Primagen's Intellectual Property position in the field of mitochondrial DNA and RNA detection as markers for adverse effects of therapy," said Dr. Bob van Gemen, Chief Executive Officer of Primagen. "It is our mission to improve the treatment of individual patients. Our molecular tests have high predictive value to avoid clinical symptoms and this license supports our current Retina(TM) Mitox(TM) products. With this license we will have a solid basis for protection in the worldwide market for these products." "Primagen is positioned to have a major impact on the molecular diagnostics market, and we are very pleased to have entered into this licensing agreement which further leverages our research results in the field of mitochondrial toxicity testing," said Dr. J.P. Heale, technology transfer Manager of the University of British Columbia and Providence Health Care. Primagen Holding B.V. is a privately held company headquartered in Amsterdam, The Netherlands. Primagen designs, develops and commercializes molecular tests that have high, individualized predictive value and improve the quality of life for patients suffering from life-threatening diseases, such as infections, AIDS and cancer.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures